期刊文献+

乳腺癌靶向治疗进展 被引量:2

下载PDF
导出
摘要 乳腺癌是女性最常见的恶性肿瘤,也是女性常见死亡原因之一。在乳腺癌治疗中,手术、辅助化疗和放疗等多学科治疗已取得显著疗效。乳腺癌是一种全身性疾病,手术和放疗是局部治疗,化疗作为一种全身治疗方法具有相对较高毒副作用,在临床应用中存在一定的局限性。乳腺癌分子生物学不断研究,激励人们开辟新的治疗模式,高效低毒的靶向治疗成为重要的治疗策略。
出处 《临床外科杂志》 2013年第7期559-562,共4页 Journal of Clinical Surgery
基金 基金项目:国家自然基金面上项目(81272514) 国家自然基金重点项目(31030061)
  • 相关文献

参考文献37

  • 1Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [ J ]. N Engl J Med, 2005,353 (16) :1659-1672.
  • 2Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J]. N Engl J Med, 2005, 353 (16): 1673-1684.
  • 3Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastu- zumab in patients with human epidermal growth factor receptor 2-positive metastat- ic breast cancer that progressed during prior trastuzumab therapy[ J]. J Clin On- eol,2010,28 (7) :1138-1144.
  • 4Gianni L, Pienkowski T, Im YH, et al. Ef- ficacy and safety of neoadjuvantpertuzum- ab and trastuzumab in women with locally advanced, in flammatory, orearly HER2- positive breast cancer(NeoSphere) :a ran- domised muhicentre, open-label, phase 2 trial [ J ]. Lancet Oneol, 2012,13 ( 1 ) : 25- 32.
  • 5Lewis Phillips GD,Li G,Dugger DL,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cyto- toxic drug conjugate [ J ]. Cancer Res, 2008,68(22) :9280-9290.
  • 6Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1 ,an HER2 anti- body-drug conjugate,given every 3 weeks to patients with HER2-positive metastatic breast cancer [ J ]. J Clin Oncol, 2010,28 (16) :2698-2704.
  • 7Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treat- ment of human epidermal growth factor re- ceptor 2 ( HER2 ) -positive breast cancer after prior HER2-directed therapy [ J ]. J Clin Oncol,2011,29(4) :398-405.
  • 8Verma S, Miles D, Gianni L, et al. Trastu- zumab emtansine for HER2 - positive ad- vanced breast cancer[ J]. N Engl J Med, 2012,367 ( 19 ) : 1783-1798.
  • 9Koch KM, Reddy N J, Cohen RB, et al. Effects of food on the relative bioavail- ability of lapatinib in cancer patients [ J ]. J Clin Onco1,2009,27 ( 8 ) : 1191-1196.
  • 10Blackwell KL,Pegram MD,Tan-Chiu E,et al. Single-agent lapatinib for HER2-overex- pressing advanced or metastatic breast cancer that progressed on first-or second- line trastuzumab-containing regimens [ J ]. Ann Oncol,2009,20(6) :1026-1031.

同被引文献28

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部